ALTERATION OF THE ENDOCANNABINOID SYSTEM IN MOUSE BRAIN DURING PRION DISEASE

被引:1
|
作者
Petrosino, S. [1 ]
Menard, B. [2 ]
Zsuerger, N. [2 ]
Di Marzo, V. [1 ]
Chabry, J. [2 ]
机构
[1] CNR, Ist Chim Biomol, Comprensorio Olivetti, Endocannabinoid Res Grp, I-80078 Pozzuoli, NA, Italy
[2] Univ Nice, Ctr Natl Rech, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France
关键词
prion; endocannabinoid; cannabinoid receptor; neurodegenerative disease; brain; mouse; CANNABINOID RECEPTORS; INFECTION; NEURONS; PRP;
D O I
10.1016/j.neuroscience.2010.12.046
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Prion diseases are neurodegenerative disorders characterized by deposition of the pathological prion protein (PrPsc) within the brain of affected humans and animals. Microglial cell activation is a common feature of prion diseases; alterations of various neurotransmitter systems and neurotransmission have been also reported. Owing to its ability to modulate both neuroimmune responses and neurotransmission, it was of interest to study the brain endocannabinoid system in a prion-infected mouse model. The production of the endocannabinoid, 2-arachidonoyglycerol (2-AG), was enhanced 10 weeks post-infection, without alteration of the other endocannabinoid, anandamide. The CB2 receptor expression was up-regulated in brains of prion-infected mice as early as 10 weeks and up to 32 weeks post-infection whereas the mRNAs of other cannabinoid receptors (CBRs) remain unchanged. The observed alterations of the endocannabinoid system were specific for prion infection since no significant changes were observed in the brain of prion-resistant mice, that is, mice devoid of the Prnp gene. Our study highlights important alterations of the endocannabinoid system during early stages of the disease long before the clinical signs of the disease. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:292 / 297
页数:6
相关论文
共 50 条
  • [21] Brain MRI studies in prion disease
    Richard Knight
    Nature Reviews Neurology, 2010, 6 : 10 - 11
  • [22] Decreased cell surface prion protein in mouse models of prion disease
    Griffin, Jennifer K.
    Terry, Linda A.
    Jackman, Roy
    Yousefi, Masoud
    Cashman, Neil R.
    NEUROREPORT, 2007, 18 (01) : 1 - 6
  • [23] The endocannabinoid system in normal and pathological brain ageing
    Bilkei-Gorzo, Andras
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2012, 367 (1607) : 3326 - 3341
  • [24] The endocannabinoid system and gut-brain signalling
    Storr, Martin A.
    Sharkey, Keith A.
    CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (06) : 575 - 582
  • [25] Targeting the endocannabinoid system in treating brain disorders
    Bahr, BA
    Karanian, DA
    Makanji, SS
    Makriyannis, A
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (04) : 351 - 365
  • [26] The endocannabinoid system in Huntington's disease
    Pazos, M. R.
    Sagredo, O.
    Fernandez-Ruiz, J.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (23) : 2317 - 2325
  • [27] Role of endocannabinoid system in brain reward.
    Martin, BR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U105 - U105
  • [28] The brain endocannabinoid system in the regulation of energy balance
    Richard, Denis
    Guesdon, Benjamin
    Timofeeva, Elena
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (01) : 17 - 32
  • [29] The Endocannabinoid System and Oligodendrocytes in Health and Disease
    Ilyasov, Alexander A.
    Milligan, Carolanne E.
    Pharr, Emily P.
    Howlett, Allyn C.
    FRONTIERS IN NEUROSCIENCE, 2018, 12
  • [30] Endocannabinoid System in Polycystic Kidney Disease
    Klawitter, Jost
    Sempio, Cristina
    Jackson, Matthew J.
    Smith, Peter H.
    Hopp, Katharina
    Chonchol, Michel
    Gitomer, Berenice Y.
    Christians, Uwe
    Klawitter, Jelena
    AMERICAN JOURNAL OF NEPHROLOGY, 2022, 53 (04) : 264 - 272